Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KC1036 + PD-1 antibody + platinum-based chemotherapy in advanced esophageal squamous cell carcinoma
CTR20254868Phase 2Active
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of connitinib in Esophageal Squamous Cell Carcinoma (ESCC), Esophagogastric junction squamous cell carcinoma, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
connitinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)Esophagogastric junction squamous cell carcinoma
Beyond the preview
Go deeper on CTR20254868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254868.